# UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects

> **NCT06272253** · EARLY_PHASE1 · UNKNOWN · sponsor: **Dr. Soetomo General Hospital** · enrollment: 250 (actual)

## Conditions studied

- COVID-19 Pandemic
- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg

## Key facts

- **NCT ID:** NCT06272253
- **Lead sponsor:** Dr. Soetomo General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-19
- **Primary completion:** 2024-03-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2024-02-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06272253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06272253, "UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06272253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*